Full-Time
Specialty pharma marketing pain and anti-infectives
$125k - $175k/yr
Atlanta, GA, USA
In Person
Approximately 80% field travel is required; some overnight or weekend travel may be required.
Bachelor's
See people who can refer or advise you
Shionogi expanded its U.S. portfolio by acquiring Victory Pharma’s marketed products, focusing on pain management and anti-infectives. Victory Pharma developed and marketed prescriptions such as Naprelan (a controlled-release naproxen) and anti-infectives like MOXATAG and KEFLEX for pain, rheumatology, and infectious diseases. Shionogi uses its existing U.S. sales force to market these FDA-approved products to doctors, quickly establishing a market presence. The strategy aims to grow in the United States by integrating Victory Pharma’s products into Shionogi’s sales and marketing reach, though Victory Pharma later faced a federal settlement related to promotional practices.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Florham Park, New Jersey
Founded
2001
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
401(k) Retirement Plan
401(k) Company Match
StreetAccount summary - asian market recap: Nikkei +3.66%, Hang Seng +0.24%, Shanghai Composite +1.47% as of 04:10 ET. Aug 05 ,2026 * Synopsis: * Asia equities rallied almost everywhere for a second consecutive day Wednesday. Technology-leaning benchmarks in South Korea, Taiwan and Japan saw the sharpest gains, while Shenzhen outperformed in mainland China. Hong Kong and Shanghai saw more modest gains while Australia's ASX reached a fresh record high. India has pared early gains while Southeast Asia is mixed. US futures higher, Europe opened with modest gains. US dollar unchanged, NZD slipped after strong jobs data, yuan and yen flat. Treasuries mixed, JGB yields lower, IGBs unchanged following RBI decision. Precious metals rallying with gold at a two-month high. Crude futures seeing more declines as Brent falls below $79/bl. Base metals higher again. Cryptocurrencies mixed. * Asia equities rallied further Wednesday following the overnight surge on Wall Street that took the S&P 500 to a fresh record high, and as futures indicate another strong open this morning in the US. SpaceX's after-hours share price decline unlikely to dissuade the bulls who received support overnight from Treasury Secretary Bessent who said a deal with Iran was imminent and an Axios report that said the US, Iran and Oman would announce an agreement to reopen the Strait of Hormuz later today. Asia equities received a further boost as the dollar remained at six-week lows, boosting local currencies and providing an additional tailwind. * In other developments, China's RatingDog Services PMI declined by more than expected and service growth in Japan also slowed; Singapore full PMI expanded further as new orders and output expanded further. Japan real wages rose for a sixth consecutive month. India's central bank kept its repo rate steady, raised its FY GDP growth forecast and lowered inflation projections but warned over risks to both forecasts from weather and geopolitical developments. * Zhongji Innolight (3308.HK) shares under pressure on a report saying the US was drafting a ban on the import of China-made optical receivers. Shein (+SHEIN) is targeting a $30-40B valuation in its Hong Kong IPO later this month, sources told Reuters. CXMT (688825.CH) is set to produce smartphone memory chips on par with industry's best, according to sources cited by Bloomberg. Shionogi's (4507.JP) CEO said the company is actively pursuing at least three acquisitions, and is considering an expansion in the US. Wistron (3231.TT) says AI server demand remains strong as quarterly profits more than double. Coupang (CPNG) posted a net quarterly loss following fines connected to its massive data breach last November. Samsung Electronics (005930.KS) and SK Hynix (000660.KS) are testing China-made chip tools as hedge against US risk, according to a Reuters report. * Digest: * Notable Gainers: * +24.5% 4062.JP (IBIDEN): reports Q1 results; revenue and operating profit beat FactSet estimates; raises FY guidance * +8.1% 669.HK (Techtronic Industries): reports H1 results * +5.0% 3034.TT (Novatek Microelectronics): reports Q2 EPS NT$10.40 vs FactSet NT$7.93 * +4.7% 9434.JP (SoftBank Corp): reports Q1 results; revenue and operating profit beat StreetAccount estimates * +4.0% 5401.JP (NIPPON STEEL): reports Q1 results; revenue and business profit beat FactSet estimates * +3.8% 196170.KS (Alteogen): signs exclusive license agreement for ALT-B4 * +1.8% 017670.KS (SK Telecom): reports Q2 results; operating profit beats StreetAccount estimates * Notable Decliners: * -6.8% 293490.KS (Kakao Games): reports Q2 results; revenue misses FactSet estimates * -6.3% 6367.JP (DAIKIN INDUSTRIES): reports Q1 results; net income misses FactSet estimates * -5.1% 4980.JP (Dexerials): reports Q1 results; revenue below FactSet estimates * -3.4% 3064.JP (MonotaRO): reports H1 results * Data: * Economic: * China July * July RatingDog Services PMI 50.4 vs consensus 53.7 and 54.1 in prior month * Composite PMI 50.8 vs 53.6 in prior month * India July * Final services PMI 53.3 vs flash 53.1 and 57.4 in prior month * Composite PMI 54.3 vs flash 54.3 and 57.1 in prior month * Japan * June average nominal wages +3.4% y/y vs consensus +3.4% and revised +3.3% in prior month * Real wages +1.6% y/y vs consensus +1.6% and revised +1.6% in prior month * July final services PMI 51.2 vs flash 51.9 and 52.2 in prior month * Composite PMI 52.7 vs flash 53.1 and 52.8 in prior month * New Zealand Q2 * Employment +0.5% q/q vs consensus +0.1% and revised +0.1% in Q1 * Unemployment rate 5.6% vs consensus 5.4% and 5.3% in Q1 * Singapore June * Retail sales y/y +4% versus +2.9% in prior month * Markets: * Nikkei: 2,342.91 or +3.66% to 66300.44 * Hang Seng: 62.90 or +0.24% to 25915.82 * Shanghai Composite: 56.15 or +1.47% to 3878.43 * Shenzhen Composite: 51.45 or +2.07% to 2537.55 * ASX200: 82.00 or +0.90% to 9227.80 * KOSPI: 239.31 or +3.76% to 6598.26 * SENSEX: (19.38) or (0.02%) to 78409.57 * Currencies: * $-¥: +0.01 or +0.01% to 157.7490 * $-KRW: (4.12) or (0.29%) to 1425.6000 * A$-$: +0.00 or +0.01% to 0.7046 * $-INR: (0.01) or (0.01%) to 95.1646 * $-CNY: (0.00) or (0.07%) to 6.7485
Shionogi launches XOCOVA in the U.S. for prevention of COVID-19 following exposure. Wednesday, July 29, 2026 Shionogi has announced the U.S. availability of XOCOVA(R)(ensitrelvir), the first and only oral antiviral approved to help prevent COVID-19 after exposure. The treatment is indicated for adults and adolescents aged 12 years and older who have been in contact with someone infected with COVID-19 and is now available through the company's U.S. subsidiary, Shionogi Inc. XOCOVA works by blocking viral replication during the period between exposure to the virus and the onset of symptoms. The treatment is taken once daily for five days, beginning with a loading dose of 375 mg on the first day, followed by 125 mg once daily on days two to five. It should be started as soon as possible and within 72 hours of exposure to an infected individual. The launch comes as health authorities continue to monitor seasonal increases in COVID-19 cases in the United States. The company highlighted that post-exposure prophylaxis is an established approach used for other infectious diseases and may help reduce the burden of COVID-19 by preventing infection after exposure. Shionogi is supporting the commercial rollout of XOCOVA through healthcare professional and public education programmes, alongside partnerships with national and regional pharmacy networks to improve product availability across the United States. The company is also offering a co-pay assistance programme for eligible commercially insured patients to help reduce out-of-pocket costs. For the U.S. market, all stages of XOCOVA manufacturing, including active pharmaceutical ingredient production, drug formulation, packaging, quality control, release testing, supply chain management and distribution, are carried out within the United States.
ALS Canada announces The Shionogi Canada Fellowship for 2025. July 21, 2026 The ALS Society of Canada (ALS Canada) is pleased to continue its collaboration with Shionogi Canada (previously Tanabe Pharma Canada) to advance excellence in ALS clinical care through The Shionogi Canada Fellowship (previously the Tanabe Pharma Canada Fellowship). This annual fellowship supports emerging clinicians and researchers who are committed to improving care for people living with ALS while strengthening their research expertise. This year, Dr. Pedro Saldanha de Castro will receive $100,000 over one year to support his work at Sunnybrook Research Institute under the supervision of Dr. Agessandro Abrahao. "Shionogi Canada's continued commitment enables ALS Canada to invest in the development of early career researchers across the ALS ecosystem," said Dr. David Taylor, Chief Scientific Officer at ALS Canada. "By applying Dr. Saldanha de Castro's novel integration of two well-studied approaches, this project may help clarify the biological drivers of disease variability in ALS, inform more precise clinical trial design, and support the development of personalized therapeutic strategies." The 2025 fellowship project titled, Innovative multimodal 7T MR imaging to assess cortical excitability and disease subtypes in ALS, aims to use advanced neuroimaging and other tests to compare two groups of people living with ALS: those whose neurons are overactive and those whose neurons are less active. By doing this, the team hopes to identify differences in brain chemistry, structure, and clinical severity between ALS subtypes. They will also validate a novel Magnetic Resonance Spectroscopy method for measuring neurochemicals across large brain regions, which could help doctors better understand the disease and develop treatments tailored to each person's needs. ALS Canada is grateful to Shionogi Canada for its continued partnership and shared commitment to fostering the next generation of ALS clinical leaders. Support the cause You can make a difference. Donations provide crucial services and information to people living with ALS and allow ALS to invest in research and advocacy dedicated to improving quality of life.
OSAKA, Japan, June 12, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereinafter, "Shionogi") today announced that, as part of its corporate venture capital (CVC) initiatives, it has invested in Dioseve, Inc. (Head Office: Tokyo, Japan; hereinafter, "Dioseve")
FDA approves Shionogi's Xocova as first oral drug to prevent COVID-19 after exposure. 2 June 2026 / 0 Comments The U.S. Food and Drug Administration (FDA) has approved Xocova (ensitrelvir), developed by Japanese pharmaceutical company Shionogi & Co., for the prevention of COVID-19 following exposure to an infected individual. The approval makes Xocova the first and only oral antiviral therapy authorized in the United States for post-exposure prophylaxis of COVID-19. The newly approved indication covers adults and adolescents aged 12 years and older who have been exposed to someone with COVID-19. Until now, no oral medication had demonstrated sufficient evidence to gain FDA approval for preventing symptomatic COVID-19 after exposure, leaving a significant gap in prevention strategies, particularly for individuals at higher risk of severe disease. FDA's decision was based on results from the Phase 3 SCORPIO-PEP study, which evaluated ensitrelvir as a post-exposure preventive treatment. According to Shionogi, the trial met its primary endpoint by significantly reducing the development of symptomatic COVID-19 among people who had recently been exposed to the virus. The study is considered the first successful Phase 3 trial of an oral antiviral for COVID-19 post-exposure prevention. The pivotal SCORPIO-PEP trial enrolled more than 2,000 participants who had been exposed to COVID-19 through infected household contacts. Symptomatic COVID-19 developed in 2.9% of participants receiving ensitrelvir compared with 9.0% in the placebo group. Additionally, 14% of patients receiving the antiviral tested positive for SARS-CoV-2 versus 21.5% in the placebo arm, highlighting the drug's potential to reduce both infection and disease development after exposure. Ensitrelvir works by blocking the SARS-CoV-2 main protease, an enzyme essential for viral replication. The drug was previously approved in Japan and Singapore for COVID-19 treatment and prevention-related indications. With the latest FDA approval, Shionogi expands its presence in the global COVID-19 therapeutics market and introduces a new option for reducing infection risk after exposure. Company officials described the approval as an important milestone in antiviral drug development. They noted that Xocova demonstrated preventive benefits regardless of vaccination status or previous COVID-19 infection history among study participants. The approval comes as healthcare systems continue to seek effective tools to protect vulnerable populations from COVID-19 outbreaks. Experts believe an oral post-exposure treatment could be particularly useful in households, healthcare settings, and other environments where close contact with infected individuals increases transmission risk.